Search

Your search keyword '"Mayer, Erica L."' showing total 466 results
Start Over Author "Mayer, Erica L."
466 results on '"Mayer, Erica L."'

103. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Author

Mayer, Ingrid A., primary, Zhao, Fengmin, additional, Arteaga, Carlos L., additional, Symmans, William F., additional, Park, Ben H., additional, Burnette, Brian L., additional, Tevaarwerk, Amye J., additional, Garcia, Sofia F., additional, Smith, Karen L., additional, Makower, Della F., additional, Block, Margaret, additional, Morley, Kimberly A., additional, Jani, Chirag R., additional, Mescher, Craig, additional, Dewani, Shabana J., additional, Tawfik, Bernard, additional, Flaum, Lisa E., additional, Mayer, Erica L., additional, Sikov, William M., additional, Rodler, Eve T., additional, Wagner, Lynne I., additional, DeMichele, Angela M., additional, Sparano, Joseph A., additional, Wolff, Antonio C., additional, and Miller, Kathy D., additional

Published
2021
Full Text
View/download PDF

104. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel

Author

Becker, Anton S., primary, Perez-Johnston, Rocio, additional, Chikarmane, Sona A., additional, Chen, Melissa M., additional, El Homsi, Maria, additional, Feigin, Kimberly N., additional, Gallagher, Katherine M., additional, Hanna, Ehab Y., additional, Hicks, Marshall, additional, Ilica, Ahmet T., additional, Mayer, Erica L., additional, Shinagare, Atul B., additional, Yeh, Randy, additional, Mayerhoefer, Marius E., additional, Hricak, Hedvig, additional, and Vargas, H. Alberto, additional

Published
2021
Full Text
View/download PDF

105. Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer

Author

Batalini, Felipe, primary, Gulhan, Doga, additional, Mao, Victor, additional, Polak, Madeline, additional, Winer, Eric P., additional, Mayer, Erica L., additional, Matulonis, Ursula A., additional, Konstantinopoulos, Panagiotis A., additional, Park, Peter, additional, and Wulf, Gerburg M., additional

Published
2021
Full Text
View/download PDF

108. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Author

Koh, Siang-Boon, primary, Ross, Kenneth, additional, Isakoff, Steven J., additional, Melkonjan, Nsan, additional, He, Lei, additional, Matissek, Karina J., additional, Schultz, Andrew, additional, Mayer, Erica L., additional, Traina, Tiffany A., additional, Carey, Lisa A., additional, Rugo, Hope S., additional, Liu, Minetta C., additional, Stearns, Vered, additional, Langenbucher, Adam, additional, Saladi, Srinivas Vinod, additional, Ramaswamy, Sridhar, additional, Lawrence, Michael S., additional, and Ellisen, Leif W., additional

Published
2021
Full Text
View/download PDF

109. A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Author

Mayer, Ingrid A., primary, Zhao, Fengmin, additional, Arteaga, Carlos L., additional, Symmans, William Fraser, additional, Park, Ben Ho, additional, Burnette, Brian Leslie, additional, Tevaarwerk, Amye Juliet, additional, Garcia, Sofia F., additional, Smith, Karen L., additional, Mayer, Erica L., additional, Sikov, William M., additional, Rodler, Eve T., additional, Wagner, Lynne I., additional, DeMichele, Angela, additional, Sparano, Joseph A., additional, Wolff, Antonio C., additional, and Miller, Kathy, additional

Published
2021
Full Text
View/download PDF

111. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy.

Author

Freret, Taylor S., Exman, Pedro, Mayer, Erica L., Little, Sarah E., and Economy, Katherine E.

Subjects
ACADEMIC medical centers, CANCER chemotherapy, RETROSPECTIVE studies, ACQUISITION of data, REGRESSION analysis, FISHER exact test, PRENATAL exposure delayed effects, SEX distribution, TREATMENT effectiveness, BIRTH weight, MEDICAL records, BREAST tumors, SMALL for gestational age, LONGITUDINAL method, PREGNANCY
Abstract

Objective  Breast cancer is one of the most frequently diagnosed cancers in pregnancy and is commonly treated with chemotherapy. To date, studies examining effects of chemotherapy during pregnancy on fetal growth have yielded conflicting results, and most are limited by small sample sizes or are nonspecific with respect to cytotoxic regimen or type of cancer treated. We sought to evaluate the effect of chemotherapy for breast cancer in pregnancy on birthweight and small for gestational age infants. Study Design  This is a retrospective cohort study of 74 women diagnosed with pathologically confirmed breast cancer during pregnancy between 1997 and 2018 at one of three academic medical centers, who had a singleton birth with known birthweight. Forty-nine received chemotherapy and 25 did not receive chemotherapy. Linear regression modeling was used to compare birthweight (by gestational age and sex-specific z -score) by chemotherapy exposure. Subanalyses of specific chemotherapy regimen and duration of chemotherapy exposure were also performed. Placental, neonatal, and maternal outcomes were also analyzed by chemotherapy exposure. Results  In the adjusted model, chemotherapy exposure was associated with lower birthweight (Δ z -score = −0.49, p  = 0.03), but similar rates of small for gestational age (defined as birthweight <10th percentile for gestational age) infants (8.2 vs. 8.0%, p  = 1.0; Fisher's exact test). Each additional week of chemotherapy (Δ z -score = −0.05, p  = 0.03) was associated with decreased birthweight, although no association was found with specific chemotherapy regimen. Chemotherapy exposure was associated with lower median placental weight percentile by gestational age (9th vs. 75th, p  < 0.05). Secondary maternal outcomes were similar between the group that did and did not receive chemotherapy. Conclusion  Chemotherapy for breast cancer in pregnancy in this cohort is associated with lower birthweight but no difference in the rate of small for gestational age infants. Key Points Chemotherapy for breast cancer in pregnancy is associated with decreased birthweight but similar rates of small for gestational age infants. Birthweight did not differ according to chemotherapy regimen. There is no difference in the rate of small for gestational age infants. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

112. Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship.

Author

Jimenez, Rachel, primary, Johnson, Andrew, additional, Horick, Nora K., additional, Hlubocky, Fay J., additional, Lei, Yvonne Y., additional, Matsen, Cindy Brown, additional, Mayer, Erica L., additional, Collyar, Deborah E., additional, LeBlanc, Thomas William, additional, Donelan, Karen, additional, Mello, Michelle, additional, and Peppercorn, Jeffrey M., additional

Published
2020
Full Text
View/download PDF

113. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

Author

Filho, Otto Metzger, primary, Giobbie-Hurder, Anita, additional, Lin, Nancy U., additional, Faggen, Meredith, additional, Come, Steven, additional, Openshaw, Thomas, additional, Constantine, Michael, additional, Walsh, Jeanna, additional, Freedman, Rachel A., additional, Schneider, Bryan, additional, Burstein, Harold J., additional, and Mayer, Erica L., additional

Published
2020
Full Text
View/download PDF

114. The effects of a clinic‐based weight loss program on health‐related quality of life and weight maintenance in cancer survivors: A randomized controlled trial.

Author

Brown, Justin C., Giobbie‐Hurder, Anita, Yung, Rachel L., Mayer, Erica L., Tolaney, Sara M., Partridge, Ann H., and Ligibel, Jennifer A.

Subjects
WEIGHT loss, QUALITY of life, RANDOMIZED controlled trials, CANCER survivors, WORRY, BODY weight, SLEEP interruptions
Abstract

Objective: The Healthy Living and Eating After Cancer Trial demonstrated that a clinic‐based weight loss program reduced body weight, as compared with a waitlist control group, over 15 weeks. Here we report the impact of the weight loss intervention on health‐related quality‐of‐life outcomes at week 15, and maintenance of weight loss to week 30. Methods: This trial randomized cancer survivors of solid tumors and hematologic malignancies (breast cancer: 76.7%) to a 15‐week group‐based weight loss program (n = 30) or a waitlist control group (n = 30). Participants were not blinded to group assignment. Participants completed a variety of health‐related quality‐of‐life outcome measures at baseline and week 15. From week 15 to week 30, participants initially randomized to the weight loss program were followed with no additional intervention, and participants initially randomized to the waitlist control group commenced the weight loss program. Results: Over the 15 weeks, the weight loss program improved physical functioning (6.2 ± 2.9; p = 0.02; d = 0.31) and reduced insomnia symptoms (−17.1 ± 7.4; p = 0.03; d = −0.30) as measured by the EORTC QLQ‐C30, and sleep disturbance (−4.9 ± 1.6; p = 0.005; d = −0.40) as measured by PROMIS, compared to waitlist control. After a weight loss of 4.6 ± 3.9 kg, from week 15 to week 30, participants who were initially randomized to the weight loss program maintained their prior weight loss (+0.6 ± 3.5 kg) and participants who were initially randomized to the waitlist control group lost weight (−3.4 ± 2.9 kg; p < 0.001). Conclusions: In cancer survivors with overweight or obesity, a 15‐week clinic‐based weight loss program improved health‐related quality‐of‐life outcomes and produced sustained weight loss to week 30. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

115. Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology.

Author

Jimenez, Rachel B., Johnson, Andrew E., Horick, Nora K., Hlubocky, Fay J., Lei, Yvonne, Matsen, Cindy B., Mayer, Erica L., Collyar, Deborah E., LeBlanc, Thomas W., Donelan, Karen, Mello, Michelle M., and Peppercorn, Jeffrey M.

Subjects
ONCOLOGISTS, PHYSICIAN-patient relations, LEGAL liability, CIVIL liability, THERAPEUTICS, ONCOLOGY
Abstract

Background: Audio recordings of oncology clinic discussions can help patients retain and understand information about their disease and treatment decisions. Access to this tool relies on acceptance of recordings by oncologists. This is the first study to evaluate experience and attitudes of oncologists toward patients recording clinic visits. Methods: Medical, radiation, and surgical oncologists from 5 US cancer centers and community affiliates were surveyed to evaluate clinicians' experience, beliefs, and practices regarding patient‐initiated recordings. Results: Among 360 oncologists (69% response rate), virtually all (93%) have experienced patients seeking to record visits. Although 75% are comfortable with recording, 25% are uncomfortable and 56% report concerns ranging from less thorough discussions to legal liability. Most (85%) always agree when patients ask to record, but 15% never or selectively allow recording. Although 51% believe recording is positive for the patient‐physician relationship, a sizable minority report that it can lead to less detailed conversations (28%) or avoidance of difficult topics, including prognosis (33%). Views did not vary based on subspecialty, practice setting, or geographic region, but older age and years in practice were associated with more positive views of recording. The majority of clinicians (72%) desire institutional policies to govern guidelines about recordings. Conclusions: Most oncologists are comfortable with patient requests to record visits, but a sizable minority remain uncomfortable, and access to recording varies solely on physician preference. This difference in care delivery may benefit from institutional policies that promote access while addressing legitimate physician concerns over privacy and appropriate use of recordings. Most oncologists are comfortable with patients recording consultations; however, 25% are uncomfortable, and more than half (56%) express concerns related to legal liability and limiting transparent discussions with patients. Institutional policies are needed to address the concerns of oncologists and enhance equitable care for patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

118. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Author

Parsons, Heather A., primary, Rhoades, Justin, additional, Reed, Sarah C., additional, Gydush, Gregory, additional, Ram, Priyanka, additional, Exman, Pedro, additional, Xiong, Kan, additional, Lo, Christopher C., additional, Li, Tianyu, additional, Fleharty, Mark, additional, Kirkner, Gregory J., additional, Rotem, Denisse, additional, Cohen, Ofir, additional, Yu, Fangyan, additional, Fitarelli-Kiehl, Mariana, additional, Leong, Ka Wai, additional, Hughes, Melissa E., additional, Rosenberg, Shoshana M., additional, Collins, Laura C., additional, Miller, Kathy D., additional, Blumenstiel, Brendan, additional, Trippa, Lorenzo, additional, Cibulskis, Carrie, additional, Neuberg, Donna S., additional, DeFelice, Matthew, additional, Freeman, Samuel S., additional, Lennon, Niall J., additional, Wagle, Nikhil, additional, Ha, Gavin, additional, Stover, Daniel G., additional, Choudhury, Atish D., additional, Getz, Gad, additional, Winer, Eric P., additional, Meyerson, Matthew, additional, Lin, Nancy U., additional, Krop, Ian, additional, Love, J. Christopher, additional, Makrigiorgos, G. Mike, additional, Partridge, Ann H., additional, Mayer, Erica L., additional, Golub, Todd R., additional, and Adalsteinsson, Viktor A., additional

Published
2020
Full Text
View/download PDF

119. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

Author

Tung, Nadine, primary, Arun, Banu, additional, Hacker, Michele R., additional, Hofstatter, Erin, additional, Toppmeyer, Deborah L., additional, Isakoff, Steven J., additional, Borges, Virginia, additional, Legare, Robert D., additional, Isaacs, Claudine, additional, Wolff, Antonio C., additional, Marcom, Paul Kelly, additional, Mayer, Erica L., additional, Lange, Paulina B., additional, Goss, Andrew J., additional, Jenkins, Colby, additional, Krop, Ian E., additional, Winer, Eric P., additional, Schnitt, Stuart J., additional, and Garber, Judy E., additional

Published
2020
Full Text
View/download PDF

120. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Author

Lehmann, Brian D., primary, Abramson, Vandana G., additional, Sanders, Melinda E., additional, Mayer, Erica L., additional, Haddad, Tufia C., additional, Nanda, Rita, additional, Van Poznak, Catherine, additional, Storniolo, Anna Maria, additional, Nangia, Julie R., additional, Gonzalez-Ericsson, Paula I., additional, Sanchez, Violeta, additional, Johnson, Kimberly N., additional, Abramson, Richard G., additional, Chen, Sheau-Chiann, additional, Shyr, Yu, additional, Arteaga, Carlos L., additional, Wolff, Antonio C., additional, and Pietenpol, Jennifer A., additional

Published
2020
Full Text
View/download PDF

121. Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)

Author

Tung, Nadine, primary, Arun, Banu, additional, Hofstatter, Erin, additional, Hacker, Michele R., additional, Toppmeyer, Deborah L., additional, Isakoff, Steven J., additional, Borges, Virginia, additional, Legare, Robert D., additional, Isaacs, Claudine, additional, Wolff, Antonio C., additional, Marcom, Paul K., additional, Mayer, Erica L., additional, Lange, Paulina B., additional, Goss, Andrew J., additional, Krop, Ian E., additional, Winer, Eric P., additional, Schnitt, Stuart J., additional, and Garber, Judy E., additional

Published
2020
Full Text
View/download PDF

124. TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.

Author

Mayer, Erica L., primary, Abramson, Vandana Gupta, additional, Jankowitz, Rachel Catherine, additional, Falkson, Carla Isadora, additional, Marcom, Paul Kelly, additional, Traina, Tiffany A., additional, Carey, Lisa A., additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Miller, Kathy, additional, Stearns, Vered, additional, Perou, Charles M., additional, Richardson, Andrea L., additional, Tung, Nadine M., additional, Barry, William Thomas, additional, Tan-Wasielewski, Zhenying, additional, Timms, Kirsten, additional, Hartman, Anne-Renee, additional, Wolff, Antonio C., additional, and Winer, Eric P., additional

Published
2019
Full Text
View/download PDF

125. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

Author

Spring, Laura, primary, Goel, Shom, additional, Sutherland, Sara, additional, Supko, Jeffrey G., additional, Juric, Dejan, additional, Isakoff, Steven J., additional, Mayer, Erica L., additional, Moy, Beverly, additional, Tolaney, Sara M., additional, and Bardia, Aditya, additional

Published
2019
Full Text
View/download PDF

127. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: RadiologyScientific Expert Panel

Author

Becker, Anton S., Perez-Johnston, Rocio, Chikarmane, Sona A., Chen, Melissa M., Homsi, Maria El, Feigin, Kimberly N., Gallagher, Katherine M., Hanna, Ehab Y., Hicks, Marshall, Ilica, Ahmet T., Mayer, Erica L., Shinagare, Atul B., Yeh, Randy, Mayerhoefer, Marius E., Hricak, Hedvig, and Vargas, H. Alberto

Abstract

Adenopathy related to COVID-19 vaccination is a frequent imaging finding that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement.

Published
2021
Full Text
View/download PDF

128. Effect of the LIVESTRONG® at the YMCA exercise program on physical activity, fitness, quality of life and fatigue in cancer survivors

Author

Irwin, Melinda L., Cartmel, Brenda, Harrigan, Maura, Li, Fangyong, Sanft, Tara, Shockro, Laura, O’Connor, Keelin, Campbell, Nancy, Tolaney, Sara M., Mayer, Erica L., Yung, Rachel, Freedman, Rachel A., Partridge, Ann H., and Ligibel, Jennifer A.

Subjects
Male, Middle Aged, Article, Patient Outcome Assessment, Physical Fitness, Risk Factors, Case-Control Studies, Neoplasms, Population Surveillance, Body Composition, Quality of Life, Humans, Female, Self Report, Survivors, Exercise, Biomarkers, Fatigue, Aged
Abstract

Physical activity (PA) has been linked to a lower risk of developing and dying of cancer, yet many cancer survivors do not exercise. In the current study, the authors evaluated the impact of the LIVESTRONG at the YMCA exercise program, available at Young Men's Christian Associations (YMCAs) across the United States, on PA, fitness, quality of life, fatigue, body composition, serum biomarkers, and program safety in cancer survivors.Cancer survivors were recruited through the Yale Cancer Center and the Dana-Farber Cancer Institute and randomized to a 12-week, twice-weekly LIVESTRONG at the YMCA exercise program at YMCAs in Connecticut or Massachusetts or to a control group. Questionnaires, dual-energy x-ray absorptiometry scans, 6-minute walk tests (6MWTs), and a fasting blood draw were completed at baseline and at 12 weeks. Intervention effects were evaluated using mixed model repeated measures analysis, with changes at 12 weeks in PA and 6MWT as the primary endpoints.A total of 186 participants were randomized (95 to the exercise group and 91 to the control group). The majority of patients were diagnosed with AJCC stage I to II cancer and 53% had breast cancer. Participants randomized to the LIVESTRONG at the YMCA program experienced increases in PA (71% exercising at ≥ 150 minutes/week vs 26% of controls; P.05) and improvements in the 6MWT (group difference: 28.9 meters [95% confidence interval, 0.3-49.0; P = .004]) and quality of life (group difference: 2.6 [95% confidence interval, 0.1-5.0; P = .04]). No adverse events were reported.The LIVESTRONG at the YMCA exercise program has the potential to impact thousands of survivors across the YMCA network and could lead to improvements in disease and psychosocial outcomes in the growing population of cancer survivors. Cancer 2017;123:1249-1258. © 2016 American Cancer Society.

Published
2016

129. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).

Author

Tung, Nadine, Arun, Banu, Hacker, Michele R., Hofstatter, Erin, Toppmeyer, Deborah L., Isakoff, Steven J., Borges, Virginia, Legare, Robert D., Isaacs, Claudine, Wolff, Antonio C., Marcom, Paul Kelly, Mayer, Erica L., Lange, Paulina B., Goss, Andrew J., Jenkins, Colby, Krop, Ian E., Winer, Eric P., Schnitt, Stuart J., and Garber, Judy E.

Published
2020
Full Text
View/download PDF

131. Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Author

Mayer, Erica L., primary, Wander, Seth Andrew, additional, Regan, Meredith M., additional, DeMichele, Angela, additional, Forero-Torres, Andres, additional, Rimawi, Mothaffar F., additional, Ma, Cynthia X., additional, Cristofanilli, Massimo, additional, Anders, Carey K., additional, Bartlett, Cynthia Huang, additional, Winer, Eric P., additional, and Burstein, Harold J., additional

Published
2018
Full Text
View/download PDF

135. Genomic profiling of ER+breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Author

Giltnane, Jennifer M., primary, Hutchinson, Katherine E., additional, Stricker, Thomas P., additional, Formisano, Luigi, additional, Young, Christian D., additional, Estrada, Monica V., additional, Nixon, Mellissa J., additional, Du, Liping, additional, Sanchez, Violeta, additional, Ericsson, Paula Gonzalez, additional, Kuba, Maria G., additional, Sanders, Melinda E., additional, Mu, Xinmeng J., additional, Van Allen, Eliezer M., additional, Wagle, Nikhil, additional, Mayer, Ingrid A., additional, Abramson, Vandana, additional, Gόmez, Henry, additional, Rizzo, Monica, additional, Toy, Weiyi, additional, Chandarlapaty, Sarat, additional, Mayer, Erica L., additional, Christiansen, Jason, additional, Murphy, Danielle, additional, Fitzgerald, Kerry, additional, Wang, Kai, additional, Ross, Jeffrey S., additional, Miller, Vincent A., additional, Stephens, Phillip J., additional, Yelensky, Roman, additional, Garraway, Levi, additional, Shyr, Yu, additional, Meszoely, Ingrid, additional, Balko, Justin M., additional, and Arteaga, Carlos L., additional

Published
2017
Full Text
View/download PDF

136. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Author

Jovanović, Bojana, primary, Mayer, Ingrid A., additional, Mayer, Erica L., additional, Abramson, Vandana G., additional, Bardia, Aditya, additional, Sanders, Melinda E., additional, Kuba, M. Gabriela, additional, Estrada, Monica V., additional, Beeler, J. Scott, additional, Shaver, Timothy M., additional, Johnson, Kimberly C., additional, Sanchez, Violeta, additional, Rosenbluth, Jennifer M., additional, Dillon, Patrick M., additional, Forero-Torres, Andres, additional, Chang, Jenny C., additional, Meszoely, Ingrid M., additional, Grau, Ana M., additional, Lehmann, Brian D., additional, Shyr, Yu, additional, Sheng, Quanhu, additional, Chen, Sheau-Chiann, additional, Arteaga, Carlos L., additional, and Pietenpol, Jennifer A., additional

Published
2017
Full Text
View/download PDF

139. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Author

Armenian, Saro H., primary, Lacchetti, Christina, additional, Barac, Ana, additional, Carver, Joseph, additional, Constine, Louis S., additional, Denduluri, Neelima, additional, Dent, Susan, additional, Douglas, Pamela S., additional, Durand, Jean-Bernard, additional, Ewer, Michael, additional, Fabian, Carol, additional, Hudson, Melissa, additional, Jessup, Mariell, additional, Jones, Lee W., additional, Ky, Bonnie, additional, Mayer, Erica L., additional, Moslehi, Javid, additional, Oeffinger, Kevin, additional, Ray, Katharine, additional, Ruddy, Kathryn, additional, and Lenihan, Daniel, additional

Published
2017
Full Text
View/download PDF

141. Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors

Author

Irwin, Melinda L., primary, Cartmel, Brenda, additional, Harrigan, Maura, additional, Li, Fangyong, additional, Sanft, Tara, additional, Shockro, Laura, additional, O'Connor, Keelin, additional, Campbell, Nancy, additional, Tolaney, Sara M., additional, Mayer, Erica L., additional, Yung, Rachel, additional, Freedman, Rachel A., additional, Partridge, Ann H., additional, and Ligibel, Jennifer A., additional

Published
2016
Full Text
View/download PDF

143. Council Clinical Perspective: Cardiovascular Health of Patients with Cancer and Cancer Survivors: A Roadmap to the Next Level

Author

Barac, Ana, Murtagh, Gillian, Carver, Joseph R., Chen, Ming Hui, Freeman, Andrew M., Herrmann, Joerg, Iliescu, Cezar, Ky, Bonnie, Mayer, Erica L., Okwuosa, Tochi M., Plana, Juan Carlos, Ryan, Thomas D., Rzeszut, Anne K., and Douglas, Pamela S.

Subjects
Cardiovascular Diseases, Data Collection, Neoplasms, Cardiology, Humans, Survivors, Medical Oncology, Article
Abstract

Many existing and emerging cancer therapies have a significant effect on the cardiovascular health of patients with cancer and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and outlines how these data provide a platform for future development of the field. We present the results of the nationwide survey on cardio-oncology services, practices, and opinions, conducted among chiefs of cardiology and program directors, which demonstrate ranges of clinical activities and identify significant interest for increased educational opportunities and expert training of cardiovascular physicians in this field. The survey respondents recognized clinical relevance but emphasized lack of national guidelines, lack of funds, and limited awareness and infrastructure as the main challenges for development and growth of cardio-oncology. We discuss potential solutions to unmet needs through interdisciplinary collaboration and the active roles of professional societies and other stakeholders.

Published
2015

144. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

Author

Naughton, Michael, Toppmeyer, Deborah, Cirrincione, Constance, Winer, Eric P., Lyss, Alan P., Perez, Edith A., mprehensive Cancer Center, San Francisco, CA, William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute, Erica L. Mayer and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA, Alvaro Moreno-Aspitia and Edith A. Perez, Mayo Clinic, Jacksonville, FL, Alan P. Lyss, Heartland Cancer Research Community Clinical Oncology Program, Michael Naughton, Washington University School of Medicine, St Louis, MO, Mayer, Erica L., Barry, William T., Leung, Eleanor, Carey, Lisa A., Rugo, Hope S., Moreno-Aspitia, Alvaro, and Hudis, Clifford

Abstract

We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.

Published
2015
Full Text
View/download PDF

145. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer

Author

Caragacianu, Diana L., primary, Mayer, Erica L., additional, Chun, Yoon S., additional, Caterson, Stephanie, additional, Bellon, Jennifer R., additional, Wong, Julia S., additional, Troyan, Susan, additional, Rhei, Esther, additional, Dominici, Laura S., additional, Economy, Katherine E., additional, Tung, Nadine M., additional, Schapira, Lidia, additional, Partridge, Ann, additional, and Calvillo, Katherina Zabicki, additional

Published
2016
Full Text
View/download PDF

146. Virtual consults: A paradigm shift for second opinions in oncology care.

Author

Velis, Stephanie A., primary, Dreyer, Nicholas J, additional, Andersen, Neil, additional, Mayer, Erica L., additional, Davids, Matthew Steven, additional, Abrams, Thomas Adam, additional, Choueiri, Toni K., additional, Meyerhardt, Jeffrey A., additional, Fisher, David Christopher, additional, Lathan, Christopher S., additional, Campos, Susana M., additional, Lane, Susan, additional, and Glynn, Philip T., additional

Published
2016
Full Text
View/download PDF

149. evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).

Author

Mayer, Erica L., Tolaney, Sara M., Brufsky, Adam, Gradishar, William John, Jhaveri, Komal L., Martin, Miguel, Moscetti, Luca, Schneeweiss, Andreas, Vidal, Gregory A., Cortazar, Patricia, Feldman, Merilin, Day, Bann-mo, and Rugo, Hope S.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results